(VIANEWS) – The Market ended the session with VIVORYON (VVY.AS) jumping 23.69% to €2.48 on Friday, after three sequential sessions in a row of losses. AEX-Index fell 0.22% to €903.61, after three consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.
About VIVORYON
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
Earnings Per Share
As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIVORYON’s stock is considered to be overbought (>=80).
More news about VIVORYON (VVY.AS).
